Clinical Trial

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-23
Trial Details
NCT Number NCT07538804
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 294 participants
Start Date 2026-07-10
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-06